Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

NefIgArd Trial Investigators

Résultat de recherche: Articleexamen par les pairs

147 Citations (Scopus)

Empreinte numérique

Plonger dans les sujets de recherche 'Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy'. Ensemble, ils forment une empreinte numérique unique.

Medicine & Life Sciences